We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Inks Deal With Synthekine to Develop Novel Cytokine Therapeutics, Delays Deal to Acquire Acceleron
Merck Inks Deal With Synthekine to Develop Novel Cytokine Therapeutics, Delays Deal to Acquire Acceleron
Merck has inked a deal worth more than $525 million with preclinical biotech Synthekine to develop and commercialize novel cytokine therapeutics that focus on autoimmune diseases.